

Contents

List of contributors	xvii	
About the editors	xxi	
Preface	xxiii	
Acknowledgments	xxv	
1. Molecular mechanisms of cell death	1	
<i>John J. Lemasters</i>		
Introduction	1	
Modes of cell death	1	
Structural features of necrosis and apoptosis	1	
Oncotic necrosis	1	
Apoptosis	3	
Cellular and molecular mechanisms underlying necrotic cell death	4	
Metastable state preceding necrotic cell death	4	
Mitochondrial dysfunction and ATP depletion	4	
Mitochondrial uncoupling in necrotic cell killing	5	
Mitochondrial permeability transition	6	
Other stress mechanisms inducing necrotic cell death	7	
Pathways to apoptosis	8	
Roles of apoptosis in biology	8	
Plasma membrane	10	
Mitochondria	10	
Cytochrome c release	10	
Regulation of the mitochondrial pathway to apoptosis	11	
Anti-apoptotic survival pathways	13	
Nucleus	14	
Endoplasmic reticulum	15	
Lysosomes	15	
Shared pathways to necrosis and apoptosis	16	
Programmed necrosis	16	
Ferroptosis	16	
Pyroptosis	17	
Necroptosis	17	
Extracellular vesicles and Exosomes	17	
Concluding remark	17	
Acknowledgments	17	
Key concepts	17	
Suggested readings	18	
2. Acute and chronic inflammation induces disease pathogenesis	19	
<i>Catherine Ptaschinski and Nicholas W. Lukacs</i>		
Introduction	19	
Leukocyte adhesion, migration, and activation	19	
Endothelial cell expression of adhesion molecules	19	
Chemoattractants	20	
Acute inflammation and disease pathogenesis	21	
Pattern recognition receptors and inflammatory responses	22	
Toll-like receptors	22	
Cytoplasmic sensors of pathogens	23	
Pattern recognition and pathologic consequences	25	
Innate lymphoid cells	25	
Regulation of acute inflammatory responses	25	
Chronic inflammation and acquired immune responses	26	
T-lymphocyte regulation of chronic inflammation	26	
B-lymphocyte and antibody responses	27	
Exacerbation of chronic diseases	28	
Tissue remodeling during acute and chronic inflammatory disease	28	
Pro-fibrogenic cytokines and growth factors involved in fibrotic tissue remodeling	29	
TGF β	29	
TNF α	30	
Key concepts	30	
Suggested readings	30	
3. Infection and host response	33	
<i>Susan L. Fink and Sheldon Campbell</i>		
Introduction	33	
Microbes and hosts—balance of power?	33	
The structure of the immune response	34	
Regulation of immunity	35	
Pathogen strategies	35	
<i>Staphylococcus aureus</i> : the extracellular battleground	36	

The innate immune system: recognition of pathogens	36	Characteristics of benign and malignant neoplasms	72
Inhibition of inflammatory cell recruitment and phagocytosis	38	Cellular differentiation and anaplasia	73
Inhibition of complement activation: you can't tag me!	38	Rate of growth	73
Inactivation of antimicrobial mechanisms	38	Presence of local invasion	75
Staphylococcal toxins and superantigens: turning the inflammatory response on the host	40	Metastasis	75
<i>Mycobacterium tuberculosis</i> and the macrophage	40	Clinical aspects of neoplasia	77
Mycobacterium and macrophage: the pathogen chooses its destiny	40	Cancer-associated pain	77
The adaptive response to <i>M. tuberculosis</i> : containment and the granuloma	41	Cancer cachexia	77
Herpes simplex virus: taking over	42	Paraneoplastic syndromes	78
Defense against viruses: subversion and sacrifice	42	Grading and staging of cancer	78
Herpes simplex virus on the high wire: a delicate balancing act	43	Key concepts	79
The African trypanosome and antibody diversity: dueling genomes	45	Suggested readings	80
Generation of antibody diversity: many ways of changing	45	5. Basic concepts in human molecular genetics	81
<i>Trypanosoma brucei</i> and evasion of the antibody response: diversity responds to diversity	46	<i>Christine M. Koellner, Kara A. Mensink and W. Edward Highsmith Jr.</i>	
HIV: the immune guerilla	49	Introduction	81
Structure and transmission of HIV—Small but deadly	49	Molecular structure of DNA, DNA transcription, and protein translation	82
Invasion of cells by HIV: into the lion's den	49	DNA Transcription	83
Perspectives	52	Protein translation	84
Key concepts	53	Molecular pathology and DNA repair mechanisms	86
Suggested readings	53	Mutation and genetic variation	86
4. Neoplasia	55	DNA replication	87
<i>William B. Coleman</i>		DNA repair	87
Introduction	55	Modes of inheritance	89
Cancer statistics and epidemiology	56	Mendelian inheritance	89
Cancer incidence	56	Non-Mendelian inheritance	91
Risk factors for the development of cancer	58	Differences in phenotypic expression can complicate pedigree analysis	92
Classification of neoplastic diseases	62	Other factors that complicate pedigree analysis	93
Benign neoplasms	64	Other considerations for pedigree construction and interpretation	93
Malignant neoplasms	64	Central dogma and rationale for genetic testing	94
Mixed cell neoplasms	65	Diagnostic and predictive molecular testing	94
Confusing terminology in cancer nomenclature	66	Considerations for molecular testing	94
Pre-neoplastic lesions	67	Benefits of molecular testing	94
Cancers of childhood	68	Risks associated with molecular testing	95
Hematopoietic neoplasms	69	Limitations associated with molecular testing	95
Hereditary cancers	71	Considerations for selection of a molecular test	95
		Allelic heterogeneity and choice of analytical methodology	95
		Specific versus scanning methods	96
		Interpretation of molecular testing results	97
		Conclusion	98
		Key concepts	98
		Suggested readings	98

6. Understanding human disease in the post-genomic era	101	Preparation of target RNA from biological and clinical specimens	114
<i>William B. Coleman</i>		Laser microdissection of tumor tissue	114
Introduction	101	Transcriptome analysis based on RNA sequencing—technical aspects	116
Structure and organization of the human genome	102	Sequencing platforms	116
DNA carries genetic information	102	Sequencing workflow	117
General structure of the human genome	103	Bioinformatics I—basic processing of RNA-seq data	118
Chromosomal organization of the human genome	103	Hardware requirements and software solutions for RNA-seq data analysis	119
Subchromosomal organization of human DNA	103	Base calling and sequencing quality	119
Overview of the human genome project	104	Read mapping and transcriptome reconstruction	119
The human genome project—objectives and strategy	104	Data visualization and inspection of read mapping	120
Human genome project findings and current status	105	Bioinformatics II—exploration and statistical evaluation of transcriptomics data	120
Impact of the human genome project on the identification of disease-related genes	106	Detection of differential expression	120
Positional gene cloning	106	Classification	121
Functional gene cloning	107	Gene selection	122
Candidate gene approach	107	Classification methods	122
Positional candidate gene approach	107	Cross-validation	122
Sources of variation in the human genome	107	Visualization	123
Types of genetic diseases	107	Clustering	123
Genetic diseases associated with gene inversions	107	Functional profiling and other enrichment analyses	124
Genetic diseases associated with gene deletions	108	Repositories for transcriptome data	125
Genetic diseases associated with gene duplications	108	Transcriptome analysis—applications in basic research and translational medicine	125
Genetic diseases and cancer	109	Transcriptomes of healthy cells	126
Cystic fibrosis	109	Transcriptome analysis in cancer pathogenesis and diagnosis	127
Phenylketonuria	109	Lymphoma transcriptomes—from gene signatures to simple gene predictors	128
Breast cancer	110	Colorectal cancer transcriptomes: consensus subtypes predict clinical outcome	131
Non-polyposis colorectal cancer	110	Breast cancer transcriptomes—identification of hidden subtypes in breast cancer within apparently homogenous cancer cell populations	132
Perspectives	111	Prediction of clinical outcome of breast cancer	134
Key concepts	111	Perspectives	137
Suggested readings	111	Key concepts	137
		Suggested readings	137
7. The human transcriptome: implications for understanding, diagnosing, and treating human disease	113	8. The human epigenome—implications for the understanding of human disease	139
<i>Matthias E. Futschik, Markus Morkel, Reinhold Schäfer and Christine Sers</i>		<i>María Berdasco and Manel Esteller</i>	
Introduction	113	Introduction	139
Gene expression analysis from single genes to microarrays—early attempts to search for genes involved in normal physiological processes and pathogenesis	113		

Epigenetic regulation of the genome	139	Key concepts	162
The human epigenome project	139	Suggested readings	162
Genomic imprinting	140		
Epigenetic regulation of imprinted genes	140	10. Integrative systems biology	165
Imprinted genes and human genetic diseases	141	<i>Gregory J. Tsongalis</i>	
Prader-Willi syndrome and Angelman syndrome	141	Introduction	165
Beckwith-Wiedemann syndrome	142	Systems biology as a paradigm shift	166
Cancer epigenetics	142	Data generation	167
DNA hypomethylation in cancer cells	143	Microarrays	167
Hypermethylation of tumor suppressor genes	143	Transcriptomics	168
Histone modifications of cancer cells	143	Genotyping	168
Epigenetic regulation of non-coding RNAs in cancer	145	Other omic disciplines	169
Aberrations in histone-modifier enzymes	145	Data integration	170
Semantic web technologies	170	Modeling systems	170
Human disorders associated with epigenetics	147	Implications for understanding disease	171
Aberrant epigenetic profiles underlying immunological, cardiovascular, neurological, and metabolic disorders	147	Redefining human diseases	172
Genetic aberrations involving epigenetic genes	147	The transition to personalized medicine	172
Applications of systems biology to medicine	173	Convergence	173
Key concepts	148	Discussion	174
Suggested readings	148	Key concepts	174
		Suggested readings	174
9. Clinical proteomics and molecular pathology	149	11. Pathology: the clinical description of human disease	177
<i>Lance A. Liotta, Justin B. Davis, Robin D. Couch, Claudia Fredolini, Weidong Zhou, Emanuel Petricoin and Virginia Espina</i>		<i>William K. Funkhouser</i>	
Understanding cancer at the molecular level: an evolving frontier	149	Introduction	177
Microdissection technology brings molecular analysis to the tissue level	149	Terms, definitions, and concepts	177
Beyond functional genomics to Cancer Proteomics	150	A brief history of approaches to disease	178
Protein Microarray tools to guide patient-tailored therapy	152	Concepts and practices before the scientific revolution	178
Molecular network analysis of human cancer tissues	153	The scientific revolution	179
Combination therapies	153	Discovery of the microscopic world	180
Phosphoprotein stability: the balance between kinases and phosphatases	155	Critical developments during the 19th century	180
Phosphatases determine phosphoprotein stability	156	Developments during the 20th century	182
Serum proteomics: an emerging landscape for early-stage cancer detection	156	Current practice of pathology	184
Application of serum proteomics to early diagnosis	156	The future of diagnostic pathology	187
Methods for discovering and validating candidate protein biomarkers	158	Individual identity at the molecular level	187
Frontiers of nanotechnology and medicine	160	Rapid cytogenetics	188
Future of cancer clinical proteomics	160	Rapid DNA sequence, RNA sequence, and RNA abundance screening	188
		Computer-based prognosis and prediction	188
		Normal ranges and disease risks by ethnic group	188
		Individual metabolic differences relevant to drug metabolism	188
		Serum biomarkers and residual disease testing	189
		Treatment by pathway, rather than by tissue diagnosis	189
		Conclusions	189

Key concepts	189	Key concepts	206
Suggested readings	190	Suggested readings	206
12. Understanding molecular pathogenesis: the biological basis of human disease and implications for improved treatment of human disease	191	14. Molecular basis of cardiovascular disease	209
<i>William B. Coleman and Gregory J. Tsongalis</i>		<i>Avrum I. Gotlieb</i>	
Introduction	191	The cells of cardiovascular organs	209
Hepatitis C virus infection	192	Vascular endothelial cells	209
Identification of the Hepatitis C virus	192	Vascular smooth muscle cells	210
Risk factors for Hepatitis C virus infection	192	Valve endocardial cells	211
Hepatitis C infection	192	Valve interstitial cells	212
Testing for Hepatitis C virus infection	193	Myeloid cells	213
Clinical course of Hepatitis C virus infection	193	Vascular progenitor/stem cells	214
Treatment of Hepatitis C infection	194	Cardiac progenitor/stem cells	214
Guided treatment of Hepatitis C virus	194	Atherosclerosis	215
Summary	195	Stage I: Plaque initiation and formation	216
Acute myeloid leukemia	195	Stage II: Adaptation stage	217
Chromosomal abnormalities in acute myelogenous leukemia	195	Stage III: Clinical stage	217
Consequence of the t(15;17) translocation in acute myelogenous leukemia	195	Ischemic heart disease	218
Detection of the t(15;17) translocation in acute myelogenous leukemia	196	Aneurysms	219
Summary	196	Vasculitis	220
Cystic fibrosis	197	Valvular heart disease	220
Cystic fibrosis transmembrane conductance regulator gene	197	Mitral valve prolapse	220
Diagnosis of cystic fibrosis	197	Calcific aortic stenosis	222
Abnormal function of CFTR in cystic fibrosis	197	Cardiomyopathies	222
Pathophysiology of cystic fibrosis	198	Cardiomyocyte structure and function	223
Summary	199	Molecular genetics and pathogenesis of hypertrophic cardiomyopathy	223
Key concepts	199	Molecular genetics and pathogenesis of dilated cardiomyopathy	223
Suggested readings	200	Cytoskeletal defects in DCM	224
13. Integration of molecular and cellular pathogenesis - a bioinformatics approach	201	Sarcomeric defects in DCM	224
<i>Jason H. Moore and Michael D. Feldman</i>		Molecular genetics and pathogenesis of arrhythmogenic right ventricular cardiomyopathy	224
Introduction	201	Molecular genetics and pathogenesis of non-compaction cardiomyopathy	225
Overview of bioinformatics	202	Channelopathies	225
Database resources	203	Lymphatic circulation	225
Data analysis	205	Key concepts	226
Data mining using R	205	Suggested readings	226
Data mining using Weka	205	15. Molecular basis of hemostatic and thrombotic diseases	229
Data mining using Orange	205	<i>Karlyn Martin, Alice D. Ma and Nigel S. Key</i>	
Interpreting data mining results	206	Introduction and overview of coagulation	229
The future of bioinformatics	206	Disorders of soluble clotting factors	231
		Fibrinogen abnormalities	233
		Prothrombin (factor II) deficiency	233
		Factor V deficiency	235
		Factor VII deficiency	235

Hemophilia A and hemophilia B (classic hemophilia and Christmas disease)	235	Hypersensitivity reactions	272
Factor X deficiency	235	Type I or immediate hypersensitivity	272
Factor XI disorders	235	Type II or antibody-mediated hypersensitivity	273
Deficiencies of factor XII, prekallikrein (PK), and high molecular weight kininogen (HK)	236	Type III or immune complex reaction	273
Factor XIII deficiency	236	Type IV or delayed-type hypersensitivity	274
Multiple clotting factor deficiencies	236	Immunologic deficiencies	274
Von Willebrand disease (VWD)	237	Primary immunodeficiencies	274
Disorders of platelet number or function	238	Acquired immunodeficiencies	278
Disorders of platelet production	238	Autoimmune diseases	280
Defects in platelet production	239	Systemic lupus erythematosus	281
Disorders of platelet function	239	Type 1 diabetes mellitus	282
Disorders of platelet destruction	241	Multiple sclerosis	282
The thrombophilias	242	Celiac disease	282
The protein C/S pathway and thrombosis	242	The hygiene hypothesis	283
Antithrombin deficiency	244	Key concepts	283
Key concepts	244	Suggested readings	284
References	245	18. Molecular basis of pulmonary disease	285
Suggested readings	246	<i>Dani S. Zander and Carol F. Farver</i>	
16. Molecular basis of lymphoid and myeloid diseases	247	Neoplastic lung and pleural diseases	285
<i>Joseph R. Biggs and Dong-Er Zhang</i>		Common molecular genetic changes in lung cancers	288
Introduction	247	Adenocarcinoma and its precursors	291
Development of the blood and lymphoid organs	247	Squamous cell carcinoma and its precursors	296
Hematopoietic stem cells	247	Large cell carcinoma	299
Hematopoietic differentiation and the role of transcription factors	251	Neuroendocrine neoplasms and their precursors	299
Hematopoietic differentiation and the role of signal transduction	252	Mesenchymal neoplasms	303
Myeloid disorders	253	Pleural malignant mesothelioma	305
Anemia	253	Non-neoplastic lung disease	308
Neutropenia	254	Chronic obstructive lung disease—emphysema/chronic bronchitis	308
Myelodysplastic syndromes	255	Bronchiectasis	311
Myelodysplastic/myeloproliferative overlap diseases and myeloproliferative neoplasms	255	Interstitial lung diseases	313
Acute myeloid leukemia	259	Idiopathic interstitial pneumonias—usual interstitial pneumonia	313
Lymphocyte disorders	262	Surfactant dysfunction diseases	315
Lymphopenia	262	Pulmonary alveolar proteinosis	315
Lymphocytosis	262	Hereditary disorders of surfactant dysfunction	317
Neoplastic problems of lymphocytes	263	Pulmonary vascular diseases	317
Key concepts	268	Pulmonary hypertension	317
Suggested readings	268	Key concepts	319
17. Molecular basis of diseases of immunity	271	Suggested readings	320
<i>David O. Beenhouwer</i>		19. Molecular basis of diseases of the gastrointestinal tract	323
Introduction	271	<i>Antonia R. Sepulveda and Armando J. Del Portillo</i>	
Immune responses	271	Introduction	323
Innate immune responses	271	Gastric cancer	323
Adaptive immune responses	271	Nonhereditary gastric cancer	324

23. Molecular basis of gynecologic diseases	409	Somatic alterations in gene expression	443
<i>Samuel C. Mok, Kwong-Kwok Wong, Karen H. Lu, Karl Munger and Zoltan Nagymanyoki</i>		MYC	443
Introduction	409	NKX3.1	444
Benign and malignant tumors of the female reproductive tract	409	PTEN	444
Cervix	409	Androgen receptor	444
Uterine corpus	413	TMPRSS2-ETS gene fusions	445
Ovary and fallopian tube	416	p27 ^{kip1}	445
Vagina and vulva	420	Telomeres	445
Disorders related to pregnancy	420	MicroRNAs	445
Gestational trophoblastic diseases	421	Epigenetics	446
Key concepts	423	GSTP1	446
Suggested readings	424	APC	446
		Key concepts	447
		Suggested readings	447
24. Molecular basis of kidney disease	425	26. Molecular biology of breast cancer	449
<i>Roderick J. Tan, Sheldon I. Bastacky and Yuhua Liu</i>		<i>Mariana Brandão, Philippe Aftimos, Hatem A. Azim Jr. and Christos Sotiriou</i>	
Introduction	425	Introduction	449
Clinical manifestations	425	Histopathological classification	449
Diagnosis of renal disease	426	Histopathological features of breast cancer	449
Serum measurements of renal function	426	Biomarkers	451
Urinalysis	426	The estrogen receptor	451
Renal biopsy	426	The progesterone receptor	452
Biomarkers for diagnosis and prognosis	426	The HER2 receptor	452
Specific glomerular and tubular diseases	427	The androgen receptor	453
Diabetic nephropathy	428	Proliferative and stromal biomarkers	454
Membranous nephropathy	428	Multifocal breast cancer	454
Focal segmental glomerulosclerosis	429	Gene expression profiling	455
IgA nephropathy	430	Microarray technology	455
Membranoproliferative glomerulonephritis	431	Molecular classification of breast cancer	455
Polycystic kidney disease	431	Gene expression signatures to refine prognosis	455
Acute kidney injury (acute tubular necrosis)	431	Signatures of immune response	457
Acute interstitial nephritis	433	Massively parallel sequencing	457
Tubulointerstitial fibrosis	433	Polymerase chain reaction (PCR)	458
Tubulointerstitial fibrosis as a final common pathway of CKD	433	Hybrid capture	458
Molecular mechanisms	434	The molecular landscape of breast cancer and novel classification	458
Conclusions	439	Molecular characterization of specific populations	458
Key concepts	439	Emerging targets	459
Suggested readings	439	Conclusions	460
		Key concepts	460
		Suggested readings	460
25. Molecular pathogenesis of prostate cancer	441	27. Molecular basis of skin disease	463
<i>William B. Coleman</i>		<i>Vesarat Wessagowit</i>	
Introduction	441	Molecular basis of healthy skin	463
Incidence and etiology of prostate cancer	442	Skin development and maintenance provide new insight into the molecular mechanisms of disease	466
Genetic contributions to prostate cancer risk	443		

Molecular pathology of mendelian genetic skin disorders	469	Genes involved in bone metastasis	506
Molecular pathology of common inflammatory skin diseases	477	miRNA and bone metastasis	507
Skin proteins as targets for inherited and acquired disorders	480	Key concepts	507
Molecular pathology of skin cancer	484	Suggested readings	507
Molecular diagnosis of skin disease	488	29. Molecular basis of diseases of the nervous system	509
New molecular mechanisms and novel therapies	490	<i>Margaret Flanagan, Joshua A. Sonnen, Christopher Dirk Keene, Robert F. Hevner and Thomas J. Montine</i>	
Key concepts	493	Anatomy of the central nervous system	509
Suggested readings	494	Microscopic anatomy	509
28. Molecular basis of bone diseases	495	Gross anatomy	511
<i>Emanuela Galliera and Massimiliano M. Corsi Romanelli</i>		Neurodevelopmental disorders	512
Introduction	495	Neural tube defects	513
Molecular basis of bone modeling and remodeling	496	Rostrocaudal and dorsoventral patterning of the neural tube: holoprosencephaly	515
Interplay between the immune system and bone: osteoimmunology and RANK-RANKL-OPG system	496	Signaling centers and transcription factor gradients in the cerebral cortex: thanatophoric dysplasia	516
Molecular basis of bone disease associated to bone matrix	496	Compartmentalization of embryonic neurogenesis	518
Osteogenesis imperfecta	496	Micrencephaly and megalencephaly	519
Autosomal dominant osteogenesis imperfecta	497	Neuronal migration and differentiation: lissencephaly	520
Recessive osteogenesis imperfecta	497	Axon growth and guidance: agenesis of the corpus callosum	522
Osteoporosis	498	Synaptogenesis, refinement, and plasticity: autism and schizophrenia	523
Estrogen regulation	498	Summary	524
Genetic regulation	498	Neurological injury: stroke, neurodegeneration, and toxicants	524
Regulation of gene expression by microRNA	499	Vascular disease and injury	525
Regulation of signaling pathways	499	Degenerative diseases	531
Regulation of local and systemic growth factors	499	Neurotoxicants	534
Molecular basis of bone disease associated with bone resorption	499	Neoplasia	537
Osteopetrosis	499	Diffuse gliomas	537
Paget disease of bone	500	Disorders of myelin	544
Molecular basis of metabolic bone disease	500	Leukodystrophies	544
Vitamin D metabolism	501	Demyelination	545
Parathyroid hormone	501	Key concepts	548
Renal osteodystrophy	502	Suggested readings	548
Molecular basis of bone infection and inflammation	502	30. Molecular diagnosis of human disease	549
Prosthetic joint infection	502	<i>Eli S. Williams and Lawrence M. Silverman</i>	
Molecular basis of bone neoplasms and bone metastasis	503	Introduction	549
Benign tumors	503	Regulatory agencies and CLIA	549
Malignant bone tumors	504	Quality assurance, quality control, and external proficiency testing	550
Molecular basis of bone metastasis	506	Method validation	550
Osteolytic and osteoblastic bone metastasis	506		

Clinical utility	551		
Molecular laboratory subspecialties	551		
Heritable disorders	551		
Infectious diseases	554		
Oncology	556		
Future directions	560		
Key concepts	561		
Suggested readings	561		
31. Molecular assessment of human diseases in the clinical laboratory	563		
<i>M. Rabie Al-Turkmani, Sophie J. Deharvengt and Joel A. Lefferts</i>			
Introduction	563		
Molecular pathology techniques	563		
PCR-based methods	563		
Array-based nucleic acid analysis	566		
Mass spectrometry	567		
Nucleic acid sequencing	567		
Methylation detection techniques	571		
Clinical applications	571		
Oncology	571		
Infectious diseases	573		
Quantitative analysis	574		
Genetic disorders	574		
Emerging technologies	576		
Liquid biopsies for molecular diagnosis	576		
Obstetrics	577		
Key concepts	577		
Suggested readings	577		
		32. Pharmacogenomics and personalized medicine in the treatment of human diseases	579
		<i>Robert D. Nerenz</i>	
		Introduction	579
		Genotyping technologies	581
		PGx and drug metabolism	581
		CYP2D6	582
		CYP2C9	583
		Drug–drug interactions	583
		PGx and drug transporters	584
		ABCB1	584
		PGx and drug targets	584
		OPRM1	584
		DRD1/2	585
		PGx applied to oncology	585
		UGT1A1	585
		TPMT	586
		Targeted therapies in oncology	586
		Estrogen receptor	586
		HER2	587
		EGFR	587
		FLT3	588
		BCR-ABL	588
		Challenges encountered	588
		Conclusion	588
		Key concepts	588
		Suggested readings	589
		Index	591

Chapter 1

Molecular mechanisms of cell death

John J. Lemasters

Departments of Drug Discovery & Pharmaceutical Sciences and Biochemistry & Molecular Biology, Medical University of South Carolina, Charleston, SC, United States

Summary

Although many stimuli cause death of cells, the mode of cell death typically follows one of two patterns. The first is necrosis, or oncosis. Oncotic necrosis is most often the result of profound metabolic disruption and is characterized by cellular swelling leading to plasma membrane rupture with release of intracellular contents. The second pattern is apoptosis, a form of programmed cell death. Apoptosis causes the orderly resorption of individual cells initiated by well-defined pathways involving activation of proteases called caspases. In contrast to necrotic cell death, which typically occurs from adenosine triphosphate (ATP) depletion, apoptosis is an ATP-requiring process. However, in both modes of cell death, mitochondrial permeabilization and dysfunction typically develop. In some instances, apoptosis and necrosis share signaling pathways as extreme endpoints on a phenotypic continuum of lost cell viability.

Introduction

A common theme in disease is death of cells. In diseases ranging from stroke to congestive heart disease to alcoholic cirrhosis of the liver, death of individual cells leads to irreversible functional loss in whole organs and ultimately mortality. For such diseases, prevention of cell death becomes a basic therapeutic goal. By contrast in neoplasia, the purpose of chemotherapy is to kill proliferating cancer cells. For either therapeutic goal, understanding the mechanisms of cell death becomes paramount.

Modes of cell death

Although many stresses and stimuli cause cell death, the mode of cell death typically follows one of two patterns. The first is necrosis, a pathological term referring to areas of dead cells within a tissue or organ. Necrosis is typically the result of an acute and usually profound metabolic disruption, such as ischemia (loss of blood supply). Since necrosis is an outcome rather than a process, the term oncosis has been introduced to describe the process leading to necrotic cell death, but the term has yet to be widely adopted. Here, the terms oncosis, oncotic necrosis, and necrotic cell death will be used synonymously to refer both to the outcome of cell death and the pathogenic events precipitating cell killing.

The second pattern is programmed cell death, most commonly manifested as apoptosis, a term derived from ancient Greek for the falling of leaves in autumn. In apoptosis, specific stimuli initiate execution of well-defined pathways leading to orderly resorption of individual cells with minimal leakage of cellular components into the extracellular space and little inflammation. Whereas necrotic cell death occurs with abrupt onset after adenosine triphosphate (ATP) depletion, apoptosis may take hours to go to completion and is an ATP-requiring process without a clearly distinguished point of no return. Although apoptosis and necrosis were initially considered separate and independent phenomena, an alternate view is emerging that apoptosis and necrosis can share initiating factors and signaling pathways to become extremes on a phenotypic continuum.

Structural features of necrosis and apoptosis

Oncotic necrosis

Cellular changes leading up to onset of necrotic cell death include formation of plasma membrane protrusions called blebs, mitochondrial swelling, dilatation of cisternae of the endoplasmic reticulum (ER), dissociation of polysomes, and cellular swelling leading to rupture with release of intracellular contents (Table 1.1, Fig. 1.1). After necrotic cell death, characteristic histological features of loss of cellular architecture, vacuolization, karyolysis (dissolution of chromatin), and increased eosinophilia soon become evident (Fig. 1.2). Cell lysis evokes an inflammatory response, attracting neutrophils and monocytes to the dead tissue to dispose of the necrotic debris by phagocytosis and defend against infection (Fig. 1.3). In organs like heart and brain with little regenerative capacity, healing occurs with scar formation, namely replacement of necrotic regions with fibroblasts, collagen and other connective tissue components. In organs like the liver that have robust regenerative capacity, cell proliferation can replace areas of necrosis with completely normal tissue within a few days. The healed liver tissue shows little or no residua of the necrotic event, but if regeneration fails, collagen deposition and fibrosis will occur instead to cause cirrhosis.

TABLE 1.1 Comparison of necrosis and apoptosis.

Necrosis	Apoptosis
Accidental cell death	Controlled cell deletion
Contiguous regions of cells	Single cells separating from neighbors
Cell swelling	Cell shrinkage
Plasmalemmal blebs without organelles	Zeiotic blebs containing large organelles
Small chromatin aggregates	Nuclear condensation and lobulation
Random DNA degradation	Internucleosomal DNA degradation
Cell lysis with release of intracellular contents	Fragmentation into apoptotic bodies
Inflammation and scarring	Absence of inflammation and scarring
Mitochondrial swelling and dysfunction	Mitochondrial permeabilization
Phospholipase and protease activation	Caspase activation
ATP depletion and metabolic disruption	ATP and protein synthesis sustained
Cell death precipitated by plasma membrane rupture	Intact plasma membrane



FIGURE 1.1 Electron microscopy of oncotic necrosis in a rat hepatic sinusoidal endothelial cell after ischemia/reperfusion. Note cell rounding, mitochondrial swelling (arrows), rarefaction of cytosol, dilatation of the ER and the space between the nuclear membranes (*), chromatin condensation, and discontinuities in the plasma membrane. Bar is 2 μ m.




FIGURE 1.2 Histology of necrosis after hepatic ischemia/reperfusion in a mouse. Note increased eosinophilia, loss of cellular architecture, and nuclear pyknosis and karyolysis. Contrast to lower left and right areas that are non-necrotic. Bar is 50 μm .




FIGURE 1.3 Scheme of necrosis and apoptosis. In oncotic necrosis, swelling leads to bleb rupture and release of intracellular constituents which attract macrophages that clear the necrotic debris by phagocytosis. In apoptosis, cells shrink and form small zeiotic blebs that are shed as membrane-bound apoptotic bodies. Apoptotic bodies are phagocytosed by macrophages and adjacent cells. Adapted with permission from Van CS, Van Den BW. *Morphological and biochemical aspects of apoptosis, oncosis and necrosis. Anat Histol Embryol* 2002;31:214–23.

Apoptosis

Unlike necrosis, which often occurs in response to an imposed unphysiological stress, apoptosis is a process of physiological cell deletion that has an opposite role to mitosis in the regulation of cell populations. In apoptosis, cell death occurs with little release of intracellular contents, inflammation, and scar formation. Individual cells undergoing

apoptosis separate from their neighbors and shrink rather than swell. Distinctive nuclear and cytoplasmic changes also occur, including chromatin condensation, nuclear lobulation and fragmentation, formation of numerous small cell surface blebs (zeiotic blebbing), and shedding of these blebs as apoptotic bodies that are phagocytosed by adjacent cells and macrophages for lysosomal degradation (Table 1.1, Fig. 1.3). Characteristic biochemical changes also occur, typically activation of a cascade of cysteine-aspartate proteases, called caspases, leakage of pro-apoptotic proteins like cytochrome *c* from mitochondria into the cytosol, internucleosomal deoxyribonucleic acid (DNA) degradation, degradation of poly(ADP-ribose) polymerase (PARP), and movement of phosphatidyl serine to the exterior leaflet of the plasmalemmal lipid bilayer. Thus, apoptosis manifests a very different pattern of cell death than oncotic necrosis (Table 1.1, Fig. 1.3).

Cellular and molecular mechanisms underlying necrotic cell death

Metastable state preceding necrotic cell death

Cellular events culminating in necrotic cell death are somewhat variable from one cell type to another, but certain events occur regularly. As implied by the term oncosis, cellular swelling is a prominent feature of oncotic necrosis. In many cell types, swelling of 30–50% occurs early after ATP depletion associated with formation of blebs on the cell surface (Fig. 1.4). These blebs contain cytosol and ER but exclude larger organelles. Bleb formation is likely due to cytoskeletal alterations after ATP depletion, whereas swelling arises from disruption of cellular ion transport. Mitochondrial swelling and dilatation of cisternae of ER and nuclear membranes accompany bleb formation (see Fig. 1.1). After longer times, a metastable state develops, which is characterized by mitochondrial depolarization, lysosomal breakdown, ion dysregulation, and accelerated bleb formation with more rapid swelling. The metastable state lasts only a few minutes and culminates in rupture of a plasma membrane bleb (Fig. 1.4). At onset of the metastable state, nonspecific pores appear to open, permitting uptake of electrolytes (principally sodium and chloride) and initiating rapid swelling driven by colloid osmotic (oncotic) forces (Fig. 1.5). Bleb rupture leads to loss of metabolic intermediates such as those that reduce tetrazolium dyes, leakage of cytosolic enzymes like lactate dehydrogenase, uptake of dyes like trypan blue, and collapse of all electrical and ion gradients. This all-or-nothing breakdown of the plasma membrane permeability barrier is long-lasting, irreversible, and incompatible with continued life of the cell.

Mitochondrial dysfunction and ATP depletion

Ischemia as occurs in strokes and heart attacks is perhaps the most common cause of necrotic cell killing. In ischemia, oxygen deprivation prevents ATP formation by mitochondrial oxidative phosphorylation, a process providing up to 95% of ATP utilized by highly aerobic tissues. The role of mitochondrial dysfunction in necrotic killing can be assessed experimentally by the ability of glycolytic substrates to rescue cells from lethal cell injury (Fig. 1.6). As an alternative source of ATP, glycolysis partially replaces ATP production lost after mitochondrial dysfunction. Maintenance of as little as 15% or 20% of normal ATP then rescues cells from necrotic death. Glycolysis also protects against toxicity from




FIGURE 1.4 Bleb rupture at onset of necrotic cell death. After metabolic inhibition with cyanide and iodoacetate, inhibitors of respiration and glycolysis, respectively, a surface bleb of the cultured rat hepatocyte on the right has just burst. Note the discontinuity of the plasma membrane surface in the scanning electron micrograph. The hepatocyte on the left is also blebbed, but the plasma membrane is still intact, and viability has not yet been lost. Bar is 5 μm . Adapted with permission from Herman B, Nieminen AL, Gores GJ, Lemasters JJ. Irreversible injury in anoxic hepatocytes precipitated by an abrupt increase in plasma membrane permeability. *FASEB J* 1988;2:146–51.




FIGURE 1.5 Plasma membrane permeabilization leading to necrotic cell death. Early after hypoxia and other metabolic stresses, ATP depletion leads to inhibition of the Na,K-ATPase and opening of monovalent cation channels causing cation gradients (Na^+ and K^+) to collapse. Swelling is limited by impermeability to anions. Later, glycine and strychnine-sensitive anion channels open to initiate anion entry and accelerate bleb formation and swelling. Swelling continues until a bleb ruptures. With abrupt and complete loss of the plasma membrane permeability barrier, viability is lost. Supravital dyes like trypan blue and propidium iodide enter the cell to stain the nucleus, and cytosolic enzymes like lactate dehydrogenase (LDH) leak out. With permission from Lemasters JJ, Qian T, He L, et al. Role of mitochondrial inner membrane permeabilization in necrotic cell death, apoptosis, and autophagy. *Antioxid Redox Signal* 2002;4:769–81.




FIGURE 1.6 Progression of mitochondrial injury. Respiratory inhibition inhibits oxidative phosphorylation and leads to ATP depletion and necrotic cell death. Glycine blocks plasma membrane permeabilization causing necrotic cell death downstream of ATP depletion. Glycolysis restores ATP and prevents cell killing. Mitochondrial uncoupling as occurs after reperfusion due to the mitochondrial permeability transition (MPT) activates the mitochondrial ATPase to futilely hydrolyze glycolytic ATP, and protection against necrotic cell death is lost. By inhibiting the mitochondrial ATPase, oligomycin prevents ATP depletion and rescues cells from necrotic cell death if glycolytic substrate is present. With permission from Lemasters JJ, Qian T, He L, et al. Role of mitochondrial inner membrane permeabilization in necrotic cell death, apoptosis, and autophagy. *Antioxid Redox Signal* 2002;4:769–81.

oxidant chemicals, suggesting that mitochondria are also a primary target of cytotoxicity in oxidative stress. However, in pathological settings like ischemia, glycolytic substrates are rapidly exhausted.

Mitochondrial uncoupling in necrotic cell killing

Mitochondrial injury and dysfunction are progressive (Fig. 1.6). Respiratory inhibition as occurs in anoxia causes ATP depletion and ultimately necrotic cell death. Glycolysis can replace this ATP supply, although only partially in highly aerobic cells, to rescue cells from necrotic killing. However, when mitochondrial injury progresses to uncoupling (inner membrane permeability to hydrogen ions), accelerated ATP hydrolysis occurs that is catalyzed by the mitochondrial ATP synthase working in reverse. Since glycolytic ATP production cannot keep pace, ATP levels fall profoundly, and

necrotic cell death ensues. In the progression from respiratory inhibition to uncoupling, mitochondria become active agents promoting ATP depletion and cell death.

Mitochondrial permeability transition

Inner membrane permeability

In oxidative phosphorylation, respiration drives translocation of protons out of mitochondria to create an electrochemical proton gradient composed of a negative inside $\Delta\Psi$ and an alkaline inside pH gradient (ΔpH). ATP synthesis is then linked to protons returning down this electrochemical gradient through the mitochondrial ATP synthase. This chemiosmotic proton circuit requires the mitochondrial inner membrane to be impermeable to ions and charged metabolites.

In some pathophysiological settings, however, the mitochondrial inner membrane abruptly becomes non-selectively permeable to solutes of molecular weight up to about 1500 Da. Ca^{2+} , oxidative stress, and numerous reactive chemicals induce this mitochondrial permeability transition (MPT), whereas cyclosporine A and pH less than 7 inhibit. The MPT causes mitochondrial depolarization, uncoupling, and large amplitude mitochondrial swelling driven by colloid osmotic forces. Opening of highly conductive permeability transition (PT) pores in the mitochondrial inner membrane underlies the MPT. Conductance is so great that opening of a single PT pore may be sufficient to cause mitochondrial depolarization and swelling.

The composition of PT pores is uncertain. In one model, PT pores are formed by the adenine nucleotide transporter (ANT) from the inner membrane, the voltage dependent anion channel (VDAC) from the outer membrane, the cyclosporine A binding protein cyclophilin D (CypD) from the matrix, and possibly other proteins (Fig. 1.7A). Although once widely accepted, the validity of this model has been challenged by genetic knockout studies showing that the MPT still occurs in mitochondria that are deficient in ANT, VDAC and CypD. More recently, PT pores are proposed to form in association with the F_1F_0 -ATP synthase (Fig. 1.7B); with spastic paraplegia 7 (SPG7), a mitochondrial AAA-type membrane protease; or with the inorganic phosphate carrier of the inner membrane. An alternative model for the PT pore is that oxidative and other stresses damage membrane proteins that then misfold and aggregate to form PT pores in association with CypD and other molecular chaperones (Fig. 1.7C).

pH-dependent ischemia/reperfusion injury

Ischemia is an interruption of blood flow and hence oxygen supply. In ischemic tissue, anaerobic metabolism causes tissue pH to decrease by a unit or more. The naturally occurring acidosis protects against necrotic cell death during ischemia and also after various toxic stresses. After reperfusion, the protection of acidotic pH is lost, and onset of necrotic cell death occurs. Much of reperfusion injury is attributable to recovery of pH, since reoxygenation at low pH prevents cell killing entirely, whereas restoration of normal pH without reoxygenation produces similar cell killing as restoration of pH with reoxygenation, a so-called pH paradox (Fig. 1.8). Cell killing in the pH paradox is linked specifically to intracellular pH and occurs independently of changes of cytosolic and extracellular free Na^+ and Ca^{2+} .

Role of the mitochondrial permeability transition in pH-dependent reperfusion injury

pH below 7 inhibits PT pores, and recovery of intracellular pH to 7 or greater after reperfusion induces the MPT (Fig. 1.8). Mitochondria depolarize during ischemia, but after reperfusion at normal pH, mitochondria repolarize initially and in parallel with recovery of intracellular pH to neutrality, the MPT occurs (Fig. 1.8 and Fig. 1.9). ATP depletion and necrotic cell death then follow. Reperfusion in the presence of PT pore blockers (e.g., cyclosporine A and its derivatives) prevents mitochondrial inner membrane permeabilization, depolarization and cell killing. Notably, cyclosporine A protects when added only during the reperfusion phase. Thus, the MPT is the proximate cause of pH-dependent cell killing in ischemia/reperfusion injury.

Oxidative stress

Reactive oxygen species (ROS) and reactive nitrogen species (RNS), including superoxide, hydrogen peroxide, hydroxyl radical, and peroxynitrite, have long been implicated in cell injury leading to necrosis (Fig. 1.10). Reperfusion after ischemia stimulates intramitochondrial ROS formation, MPT onset and cell death (Fig. 1.9). In neurons, excitotoxic stress with glutamate and N-methyl-D-aspartate (NMDA) receptor agonists also stimulates mitochondrial ROS formation, leading to the MPT and excitotoxic injury.




FIGURE 1.7 Models of mitochondrial permeability transition pores. In one model (A), PT pores are composed of the adenine nucleotide translocator (ANT) from the inner membrane (IM), cyclophilin D (CypD) from the matrix and the voltage-dependent anion channel (VDAC) from the outer membrane (OM). Other proteins, such as the peripheral benzodiazepine receptor (PBR), hexokinase (HK), creatine kinase (CK), and Bax may also contribute. PT pore openers include Ca^{2+} , inorganic phosphate (P_i), reactive oxygen and nitrogen species (ROS, RNS), and oxidized pyridine nucleotides ($NAD(P)^+$) and glutathione (GSSG). A newer model (B) has PT pores forming in F_1F_0 -ATP synthase dimers at the interface between monomers (or possibly in association with c-rings). OSCP (oligomycin sensitivity-conferring protein), a, b, c, d, e, f, g, α , β , γ , δ , ϵ , A6L and F8 are subunits of the synthase. An alternative proposal (C) suggests that oxidative and other damage to integral inner membrane proteins leads to misfolding. These misfolded proteins aggregate at hydrophilic surfaces facing the hydrophobic bilayer to form aqueous channels. CypD and other chaperones block conductance of solutes through these nascent PT pores. High matrix Ca^{2+} acting through CypD leads to PT pore opening, an effect blocked by cyclosporine A (CsA). As misfolded protein clusters exceed the number of chaperones to regulate them, constitutively open channels form. Such unregulated PT pores are not dependent on Ca^{2+} for opening and are not inhibited by CsA. Adapted with permission from Kim JS, He L, Qian T, Lemasters JJ. Role of the mitochondrial permeability transition in apoptotic and necrotic death after ischemia/reperfusion injury to hepatocytes. *Curr Mol Med* 2003;3:527–35.

Iron potentiates injury in a variety of diseases and is an important catalyst for hydroxyl radical formation from superoxide and hydrogen peroxide (Fig. 1.10). During oxidative stress, acetaminophen hepatotoxicity and hypoxia/ischemia, lysosomes release chelatable (loosely bound) iron with consequent pro-oxidant cell damage. This iron is taken up into mitochondria by the mitochondrial calcium uniporter and helps catalyze mitochondrial ROS generation. Iron chelation with desferal prevents mitochondrial ROS formation and decreases cell death.

Other stress mechanisms inducing necrotic cell death

Poly (ADP-ribose) polymerase

Single strand breaks induced by ultraviolet (UV) light, ionizing radiation, and ROS (particularly hydroxyl radical and peroxynitrite) activate PARP. PARP transfers ADP-ribose from NAD^+ to the strand breaks and elongates ADP-ribose polymers attached to the DNA. Excess consumption of NAD^+ in this fashion leads to NAD^+ depletion, disruption of




FIGURE 1.8 Mitochondrial inner membrane permeabilization in adult rat cardiac myocytes after ischemia and reperfusion. After loading mitochondria of cardiac myocytes with calcein, cells were subjected to 3 h of anoxia at pH 6.2 (ischemia) followed by reoxygenation at pH 7.4 (A), pH 6.2 (B), or pH 7.4 with 1 μ M CsA (C). Red-fluorescing propidium iodide was present to detect loss of cell viability. Note that green calcein fluorescence was retained by mitochondria at the end of ischemia (1 min before reperfusion), indicating that PT pores had not opened. After reperfusion at pH 7.4, mitochondria progressively released calcein over 30 min at which time calcein was nearly evenly distributed throughout cytosol. After 60 min, all cellular calcein was lost, and the nucleus stained with PI, indicating loss of viability. After reperfusion at pH 6.2 (B) or at pH 7.4 in the presence of CsA (C), calcein was retained and cell death did not occur. Thus, reperfusion at pH 7.4 induced onset of the MPT and necrotic cell death that were blocked with CsA and acidotic pH. Adapted with permission from Kim JS, Jin Y, Lemasters JJ. Reactive oxygen species, but not Ca^{2+} overloading, trigger pH- and mitochondrial permeability transition-dependent death of adult rat myocytes after ischemia-reperfusion. *Am J Physiol Heart Circ Physiol* 2006;290:H2024–34.

ATP-generation, and ATP depletion-dependent cell death. PARP-dependent necrosis is an example of programmed necrosis, since PARP actively promotes a cell death-inducing pathway that otherwise would not occur. Necrotic cell death also frequently occurs when apoptosis is interrupted, as by caspase inhibition. Such caspase-independent cell death is the consequence of mitochondrial dysfunction or other metabolic disturbance.

Plasma membrane injury

An intact plasma membrane is essential for cell viability. Detergents and pore-forming agents like mastoparan from wasp venom defeat the barrier function of the plasma membrane and cause immediate cell death. Immune-mediated cell killing can act similarly. In particular, complement mediates formation of a membrane attack complex that in conjunction with antibody lyses cells. Complement component 9, an amphipathic molecule, inserts through the cell membrane, polymerizes, and forms a tubular channel visible by electron microscopy. Indeed, a single membrane attack complex is sufficient to cause lysis of an individual erythrocyte.

Pathways to apoptosis

Roles of apoptosis in biology

Apoptosis is an essential event in both the normal life of organisms and in pathobiology. In development, apoptosis sculpts and remodels tissues and organs, for example, by creating clefts in limb buds to form fingers and toes. Apoptosis is also responsible for reversion of hypertrophy to atrophy and immune surveillance-induced killing of pre-neoplastic and virally infected cells. Each of several organelles can give rise to signals initiating apoptosis. Often these signals converge on mitochondria as a common pathway to apoptotic cell death. In most apoptotic signaling, activation of caspases 3 or 7




FIGURE 1.9 Mitochondrial ROS formation after reperfusion. Myocytes were co-loaded with red-fluorescing tetramethylrhodamine methylester (TMRM) and green-fluorescing chloromethylchloro fluorescein (cmDCF) to monitor mitochondrial membrane potential and ROS formation, respectively. At the end of 3 h of ischemia, mitochondria were depolarized (lack of red TMRM fluorescence). After 20 min of reperfusion, mitochondria took up TMRM, indicating repolarization, and cmDCF fluorescence increased progressively inside mitochondria (A). Subsequently, hypercontraction and depolarization occurred after 40 min, and viability was lost within 120 min, as indicated by nuclear labeling with red-fluorescing propidium iodide. When cyclosporine A was added at reperfusion (B), mitochondria underwent sustained repolarization, and hypercontraction and cell death did not occur. Nonetheless, mitochondrial cmDCF fluorescence still increased. By contrast, reperfusion with antioxidants prevented ROS generation and MPT onset with subsequent cell death (data not shown). Thus, mitochondrial ROS generation induces the MPT and cell death after ischemia/reperfusion. Adapted with permission from Kim JS, Jin Y, Lemasters JJ. Reactive oxygen species, but not Ca^{2+} overloading, trigger pH- and mitochondrial permeability transition-dependent death of adult rat myocytes after ischemia-reperfusion. *Am J Physiol Heart Circ Physiol* 2006;290:H2024–34.

from a family of caspases (Table 1.2) begins execution of the final and committed phase of apoptotic cell death. Caspase 3/7 has many targets. Degradation of the nuclear lamina and cytokeratins contributes to nuclear remodeling, chromatin condensation, and cell rounding. Endonuclease activation leads to internucleosomal DNA cleavage. The resulting DNA fragments have lengths in multiples of 190 base pairs, the nucleosome to nucleosome repeat distance. In starch gel electrophoresis, these fragments produce a characteristic ladder pattern. DNA strand breaks are also recognized in tissue sections by the terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling (TUNEL) assay. Additionally, caspase activation leads to cell shrinkage, phosphatidyl serine externalization on the plasma membrane, and formation of numerous small surface blebs (zeiosis). Unlike necrotic blebs, zeiotic blebs contain membranous organelles. However, not all apoptotic changes depend on caspase 3/7 activation. For example, release of apoptosis-inducing factor (AIF) from mitochondria and its translocation to the nucleus promotes DNA degradation in a caspase 3-independent fashion.

Pathways leading to activation of caspase 3 and related effector caspases like caspase 7 are complex and variable between cells and specific apoptosis-instigating stimuli, and each major cellular structure can originate its own set of unique signals to induce apoptosis (Fig. 1.11). Pro-apoptotic signals are often associated with specific damage or perturbation to the organelle involved. Consequently, cells choose death by apoptosis rather than life with organelle damage.




FIGURE 1.10 Iron-catalyzed free radical generation. Oxidative stress causes oxidation of GSH and NAD(P)H, important reductants in antioxidant defenses, promoting increased net formation of superoxide ($O_2^{\bullet-}$) and hydrogen peroxide (H_2O_2). Superoxide dismutase converts superoxide to hydrogen peroxide, which is further detoxified to water by catalase and peroxidases. In the iron-catalyzed Haber Weiss reaction (or Fenton reaction), superoxide reduces ferric iron (Fe^{3+}) to ferrous iron (Fe^{2+}), which reacts with hydrogen peroxide to form the highly reactive hydroxyl radical (OH^{\bullet}). Hydroxyl radical reacts with lipids to form alkyl radicals (L^{\bullet}) that initiate an oxygen-dependent chain reaction generating peroxyl radicals (LOO^{\bullet}) and lipid peroxides (LOOH). Iron also catalyzes a chain reaction generating alkoxyl radicals (LO^{\bullet}) and more peroxyl radicals. Nitric oxide synthase catalyzes formation of nitric oxide (NO) from arginine. Nitric oxide reacts rapidly with superoxide to form unstable peroxynitrite anion ($ONOO^-$), which decomposes to nitrogen dioxide and hydroxyl radicals. In addition to attacking lipids, these radicals also attack proteins and nucleic acids.

Plasma membrane

The plasma membrane is the target of many receptor-mediated signals. In particular, death ligands (*e.g.*, tumor necrosis factor α , or $TNF\alpha$; Fas ligand or FasL; tumor necrosis factor-related apoptosis-inducing ligand, or TRAIL) acting through their corresponding receptors (TNF receptor 1, or TNFR1; Fas; death receptor 4 and 5, or DR4/5) initiate activation of apoptotic pathways. Binding of ligands like $TNF\alpha$ leads to receptor trimerization and formation of a complex with adapter proteins (*e.g.*, TNF receptor-associated death domain protein, or TRADD). After receptor dissociation, a death-inducing signaling complex (DISC) forms through association with Fas-associated protein with death domain (FADD) and pro-caspase 8, which are internalized. Pro-caspase 8 becomes activated and in turn proteolytically activates other downstream effectors (Fig. 1.12). In Type I signaling, caspase 8 activates caspase 3 directly, whereas in Type II signaling, caspase 3 cleaves Bid (novel BH3 domain-only death agonist) to truncated Bid (*t*Bid) to activate a mitochondrial pathway to apoptosis. Similar signaling occurs after association of FasL with Fas (also called CD95) and TRAIL with DR4/5.

Many events modulate death receptor signaling in the plasma membrane. For example, the extent of gene and surface expression of death receptors is an important determinant in cellular sensitivity to death ligands. Stimuli like hydrophobic bile acids can recruit death receptors to the cell surface and sensitize cells to death-inducing stimuli. Surface recruitment of death receptors may also lead to self-activation even in the absence of ligand. Death receptors localize to lipid rafts containing cholesterol and sphingomyelin. After death receptor activation, ceramide forms from sphingomyelin hydrolysis, which promotes raft coalescence and formation of molecular platforms that cluster components of DISC. Glycosphingolipids, such as ganglioside GD3, also integrate into DISCs to promote apoptosis.

Mitochondria

Cytochrome c release

Bid is a BH3 only domain member of the B-cell lymphoma-2 (Bcl2) family that includes both pro- and anti-apoptotic proteins (Fig. 1.13). *t*Bid formed after caspase 8 activation translocates to mitochondria where it interacts with either

TABLE 1.2 Mammalian caspases.

Initiator caspases	Molecular weight of proenzyme (kDa)	Active subunits (kDa)	Prodomain	Amino acid target sequence for proteolysis
Caspase 2	51	19/12	Long with CARD	VDVAD
Caspase-8	55	18/11	Long with two DED	(L/V/D)E(T/V/I)D
Caspase-9	45	17/10	Long with CARD	(L/V/I)EHD
Caspase-10	55	17/12	Long with two DED	(I/V/L)EXD
Caspase-12	50	20/10	Long with CARD	ATAD
Effector caspases				
Caspase-3	32	17/12	Short	DE(V/I)D
Caspase-6	34	18/11	Short	(T/V/I)E(H/V/I)D
Caspase-7	35	20/12	Short	DE(V/I)D
Inflammatory caspases				
Caspase 1	45	20/10	Long with CARD	(W/Y/F)EHD
Caspase 4	43	20/10	Long with CARD	(W/L)EHD
Caspase 5	48	20/10	Long with CARD	(W/L/F)EHD
Caspase 11	42	20/10	Long with CARD	(V/I/P/L)EHD
Other caspases				
Caspase 14	42	20/10	Short	(W/I)E(T/H)D

Caspases are evolutionarily conserved aspartate specific cysteine-dependent proteases that function in apoptotic and inflammatory signaling. Initiator caspases are involved in the initiation and propagation of apoptotic signaling, whereas effector caspases act on a wide variety of proteolytic substrates to induce the final and committed phase of apoptosis. Initiator and inflammatory caspases have large prodomains containing oligomerization motifs such as the caspase recruitment domain (CARD) and the death effector domain. Effector caspases have short pro-domains and are proteolytically activated by large pro-domain caspases and other proteases. Proteolytic cleavage of pro-caspase precursors forms separate large and small subunits that assemble into active enzymes consisting of two large and two small subunits. Caspase activation occurs in multimeric complexes that typically consist of a platform protein that recruits pro-caspases either directly or by means of adaptors. Such caspase complexes include the apoptosome and the death-inducing signaling complex (DISC). Caspase 14 plays a role in terminal keratinocyte differentiation in cornified epithelium.

Bak (Bcl2 homologous antagonist/killer) or Bax (a conserved homolog that heterodimerizes with Bcl2), two other pro-apoptotic Bcl2 family members, to induce cytochrome *c* release through the outer membrane into the cytosol. Cytochrome *c* in the cytosol interacts with apoptotic protease activating factor-1 (Apaf-1) and pro-caspase 9 to assemble haptomeric apoptosomes and an ATP (or deoxyadenosine triphosphate, or dATP)-dependent cascade of caspase 9 and caspase 3 activation.

Cytochrome *c* release from the space between the mitochondrial inner and outer membranes appears to occur via formation of specific pores in the mitochondrial outer membrane. Except for the requirement for either Bak or Bax, the molecular composition and properties of cytochrome *c* release channels remain incompletely understood. Alternatively, cytochrome *c* release can occur as a consequence of the MPT due to mitochondrial swelling and rupture of the outer membrane.

After the MPT, progression to apoptosis or necrosis depends on other factors. If the MPT occurs rapidly and affects most mitochondria of a cell, as happens after severe oxidative stress and ischemia/reperfusion, a precipitous fall of ATP (and dATP) will occur that actually blocks apoptotic signaling by inhibiting (d)ATP-requiring caspase 9/3 activation. With ATP depletion, oncotic necrosis ensues. However, when alternative sources for ATP generation are present (*e.g.*, glycolysis), then necrosis is prevented and caspase 9/3 becomes activated, and caspase-dependent apoptosis occurs instead (Fig. 1.14). Crosstalk between apoptosis and necrosis also occurs in other ways. For example, after TNF α binding to TNRR1, recruitment of receptor-interacting serine/threonine-protein kinase 1 (RIPK1) can activate NADPH oxidase leading to superoxide generation and sustained activation of c-Jun nuclear kinase (JNK), resulting in oncotic necrosis rather than apoptosis.

Regulation of the mitochondrial pathway to apoptosis

Mitochondrial pathways to apoptosis vary depending on expression of pro-caspases, Apaf-1, and other proteins. Some terminally differentiated cells, particularly neurons, do not respond to cytochrome *c* with caspase activation and




FIGURE 1.11 Scheme of apoptotic signaling from organelles. See text for details. Adapted with permission from Lemasters JJ. Dying a thousand deaths: redundant pathways from different organelles to apoptosis and necrosis. *Gastroenterology* 2005;129:351–60.

apoptosis, which may be linked to lack of Apaf-1 expression. Anti-apoptotic Bcl2 proteins, like Bcl2, Bcl extra long (Bcl-xL), and myeloid cell leukemia sequence 1 (Mcl-1), block apoptosis and are frequently overexpressed in cancer cells (Fig. 1.13). Anti-apoptotic Bcl2 family members form heterodimers with pro-apoptotic family members like Bax and Bak, to prevent the latter from oligomerizing into cytochrome *c* release channels.

Inhibitor of apoptosis proteins (IAPs), including X-linked inhibitor of apoptosis protein (XIAP), cellular IAP1 and 2 (cIAP1/2), and survivin, oppose apoptotic signaling by inhibiting caspase activation. Many IAPs recruit E2 ubiquitin-conjugating enzymes to promote ubiquitination of target proteins and subsequent proteasomal degradation. Some IAPs inhibit apoptotic pathways upstream of mitochondria at caspase 8, whereas others like XIAP inhibit caspase 9/3 activation downstream of mitochondrial cytochrome *c* release. Additional proteins like Smac suppress the action of IAPs, providing an “inhibitor of the inhibitor” effect promoting apoptosis. Smac is a mitochondrial intermembrane protein that is released with cytochrome *c*. Smac inhibits XIAP and promotes apoptotic signaling after mitochondrial signaling. Thus, high Smac to XIAP ratios favor caspase 3 activation after cytochrome *c* release. Other pro-apoptotic proteins released from the mitochondrial intermembrane space during apoptotic signaling include AIF, endonuclease G, and high temperature requirement A2 (HtrA2/Omi, a serine protease that degrades IAPs).

Disruption of mitochondrial function induces fragmentation of larger filamentous mitochondria into smaller more spherical structures. Such changes are also often prominent in apoptosis. Mitochondrial fission is mediated by dynamin-like protein type 1 (Drp1), a large cytosolic GTPase mechanoenzyme, and fission-1 (Fis1) in the outer membrane. Drp1 forms complexes with pro-apoptotic Bcl2 family members like Bax to promote cytochrome *c* release during apoptosis. Mitochondrial fusion depends on optic atrophy-1 (Opa1) in the inner membrane, which is mutated in dominant optic atrophy, and mitofusin 1 and 2 (Mfn1/2), two proteins in the outer membrane. Fission events in mitochondria seem to promote apoptotic signaling, since dynamin-like protein type 1 (Drp-1) overexpression promotes apoptosis, whereas Mfn1/2 overexpression retards apoptosis.